stockportfolio.pro
Cytokinetics, Incorporated (CYTK)
Healthcare · Biotechnology · NasdaqGS
Cytokinetics, Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.41M | $13.37M | $31.50M | $26.87M | $55.83M | $70.43M | $94.59M | $7.53M | $18.47M | $88.04M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $16.45M | $-127.79M | $-106.29M | $-121.69M | $-127.29M | $-215.31M | $-388.95M | $-526.24M | $-589.53M | $-784.96M |
| Net margin | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
Source: Cytokinetics, Incorporated SEC filings (10-K). 27 years of history available in the interactive view.
Explore 27 years of Cytokinetics, Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CYTK in your portfolio →
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics, Incorporated — frequently asked questions
What is Cytokinetics, Incorporated's revenue?
Cytokinetics, Incorporated (CYTK) reported revenue of $88.04M for fiscal year 2025, up 376.6% from the prior year, according to its SEC filings.
Is Cytokinetics, Incorporated profitable?
No — CYTK reported a net loss of $-784.96M in fiscal 2025.
What is CYTK's P/E ratio?
Cytokinetics, Incorporated trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Cytokinetics, Incorporated growing?
CYTK's revenue grew at roughly 9.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Cytokinetics, Incorporated's official SEC filings (10-K and 10-Q), covering 27 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.